Pfizer has announced the results of the 2/3 phase evaluation of the inhibition protease for Covid-19 in the interim analysis of the patient-HR, revealed that the antiviri pills Paxlovid reduced the risk of inpatient and death of 89 percent in high-risk adults who have Covid -19. Protective effects compared to a group of patients who receive placebo drugs, opening the way for the potential for new home care that can drastically reduce the amount of inpatient.
What is Paxlovid?
Paxlovid Pfizer is a new oral antivirus pill developed as a potential treatment of severe Covid-19. This drug is a protease inhibitor which specifically blocks the SARS-COV-2-that-that-that is, blocking the enzymes used by the virus to replicate, an activity that has the potential to lead to more severe infections and increases the risk of death.
Paxlovid is a candidate for oral treatment PF-07321332 which is given together with a low dose of ritonavir, antiretroviral drug. By combining SARS-COV-2 protease inhibitors with antiretroviral drugs, Pfizer said that the therapy of the antiviri allows PF-07321332 to remain active in the patient’s body for a longer period of time while maintaining a higher concentration, making it more effective against the virus.
Provisional analysis results
Pfizer announced the results of the temporary analysis of the 2/3 Phase Epic-HR study on November 5, which stated that Paxlovid significantly reduced the risk of inpatient and death due to COVID-19 among high-risk patients. When looking at the whole participant in this study, no patient received Paxlovid died for 28 days compared to 10 patients who received a placebo and died of the disease.Participants registered in the 2/3 epic-HR phase study at the end of September; Data about a total of 1,219 adult patients is used in primary analysis that has been issued by the company. All participants have a Covid-19 infection confirmed using a laboratory test, with confirmation carried out in a five-day period and the symptoms ranging from mild to moderate.
Likewise, all participants have at least one factor that increases the risk of severe infection. For five days, the participants were randomly divided into two groups, one was given a placebo and the other was given Paxlovid every 12 hours.
This analysis found that oral covid-19 pfizer antivirus therapy trimmed the risk of severe results with 89 percent, with several participants reporting “side effects,” which were mostly mild. Compared to placebo drugs, fewer patients who receive Paxlovid experienced a “serious side effect” at 1.7 percent compared to 6.6 percent.
Can you get Pfizer’s COVID-19 pill?
The results of the interim analysis are only one step towards potential authorization and finally approval from Paxlovid, which is not yet available for patients. The results are promising and thus, Pfizer said that he followed recommendations from the Independent Data Monitoring Committee to stop registering additional patients in this study.
The reason for this decision was “extraordinary efficacy shown in this result,” Pfizer explained, noting that he had a plan to send this data to the FDA as part of the reproduction for the authorization of the Emergency Use of Eventually (EUA). This drug has not been permitted or approved at this time.
Assuming Pfizer finally gets an emergency use of the FDA for Paxlovid, the drug will be the first oral antivirus treatment of its type designed to overcome SARS-COV-2, reduce the risk of severe COVID-19 infection, and has the potential to reduce the decrease in the amount of inpatient. caused by this disease. In addition to reducing the severity of the disease in patients, Pfizer said the medicine might also have the potential to reduce the chance of a person to experience infection if they are exposed to SARS-COV-2.